Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 11Sarcoma 5Gastrointestinal 3Other solid neoplasm 2Myeloid 2Genitourinary 2CNS 2Thoracic 1Gynecologic 1

Conditions

Solid Tumor 1Mesothelioma 1

Interventions

Cisplatin 42Pemetrexed 31Carboplatin 28Nivolumab 21pembrolizumab 19Gemcitabine 19atezolizumab 13Etoposide 13Injections 12Ipilimumab 11Cyclophosphamide 11Radiotherapy 10Oxaliplatin 10Filgrastim 10Docetaxel 10Bevacizumab 10tislelizumab 9Vincristine 9Specimen Handling 9durvalumab 8Paclitaxel 8Capecitabine 8tremelimumab 7toripalimab 7lenvatinib 7Everolimus 7spartalizumab 6olaparib 6niraparib 6Vinorelbine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × tazemetostat × Other solid neoplasm × Clear all
NCT05023655 2026-03-17

Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

Prisma Health-Upstate

Phase 2 Terminated
20 enrolled
Other solid neoplasm

Solid Tumor

NCT02860286 2021-04-09

Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma

Epizyme, Inc.

Phase 2 Completed
74 enrolled 23 charts
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡